The global Metabolic Disorder Therapeutics market is projected to grow from US$ 50150 million in 2024 to US$ 64560 million by 2030, at a Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period.

Metabolic Disorder Therapeutics Market

Market Analysis and Insights: Global Metabolic Disorder Therapeutics Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Covers:

This report presents an overview of global market for Metabolic Disorder Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Metabolic Disorder Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Metabolic Disorder Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metabolic Disorder Therapeutics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Metabolic Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Metabolic Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Metabolic Disorder Therapeutics Market Report

Report Metric	Details
Report Name	Metabolic Disorder Therapeutics Market
Accounted market size in 2024	US$ 50150 in million
Forecasted market size in 2030	US$ 64560 million
CAGR	4.3
Base Year	2024
Forecasted years	2025 - 2030
Segment by Type	Lysosomal Storage Diseases Diabetes Obesity Inherited Metabolic Disorders Hypercholesterolemia
Segment by Application	Oral Parenteral Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Metabolic Disorder Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disorder Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metabolic Disorder Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Metabolic Disorder Therapeutics Market growing?

Ans: The Metabolic Disorder Therapeutics Market witnessing a CAGR of 4.3 during the forecast period 2025-2030.

What is the Metabolic Disorder Therapeutics Market size in 2030?

Ans: The Metabolic Disorder Therapeutics Market size in 2030 will be US$ 64560 million.

Who are the main players in the Metabolic Disorder Therapeutics Market report?

Ans: The main players in the Metabolic Disorder Therapeutics Market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc., CymaBay Therapeutics, Inc.

What are the Application segmentation covered in the Metabolic Disorder Therapeutics Market report?

Ans: The Applications covered in the Metabolic Disorder Therapeutics Market report are Oral, Parenteral, Others

What are the Type segmentation covered in the Metabolic Disorder Therapeutics Market report?

Ans: The Types covered in the Metabolic Disorder Therapeutics Market report are Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Lysosomal Storage Diseases

1.2.3 Diabetes

1.2.4 Obesity

1.2.5 Inherited Metabolic Disorders

1.2.6 Hypercholesterolemia

1.3 Market by Application

1.3.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Oral

1.3.3 Parenteral

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Metabolic Disorder Therapeutics Market Perspective (2019-2030)

2.2 Global Metabolic Disorder Therapeutics Growth Trends by Region

2.2.1 Metabolic Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Metabolic Disorder Therapeutics Market Dynamics

2.3.1 Metabolic Disorder Therapeutics Industry Trends

2.3.2 Metabolic Disorder Therapeutics Market Drivers

2.3.3 Metabolic Disorder Therapeutics Market Challenges

2.3.4 Metabolic Disorder Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Metabolic Disorder Therapeutics by Players

3.1.1 Global Metabolic Disorder Therapeutics Revenue by Players (2019-2024)

3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Metabolic Disorder Therapeutics, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio

3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2023

3.5 Global Key Players of Metabolic Disorder Therapeutics Head office and Area Served

3.6 Global Key Players of Metabolic Disorder Therapeutics, Product and Application

3.7 Global Key Players of Metabolic Disorder Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Disorder Therapeutics Breakdown Data by Type

4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030)

5 Metabolic Disorder Therapeutics Breakdown Data by Application

5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Metabolic Disorder Therapeutics Market Size (2019-2030)

6.2 North America Metabolic Disorder Therapeutics Market Size by Type

6.2.1 North America Metabolic Disorder Therapeutics Market Size by Type (2019-2024)

6.2.2 North America Metabolic Disorder Therapeutics Market Size by Type (2025-2030)

6.2.3 North America Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

6.3 North America Metabolic Disorder Therapeutics Market Size by Application

6.3.1 North America Metabolic Disorder Therapeutics Market Size by Application (2019-2024)

6.3.2 North America Metabolic Disorder Therapeutics Market Size by Application (2025-2030)

6.3.3 North America Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

6.4 North America Metabolic Disorder Therapeutics Market Size by Country

6.4.1 North America Metabolic Disorder Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

6.4.3 North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Metabolic Disorder Therapeutics Market Size (2019-2030)

7.2 Europe Metabolic Disorder Therapeutics Market Size by Type

7.2.1 Europe Metabolic Disorder Therapeutics Market Size by Type (2019-2024)

7.2.2 Europe Metabolic Disorder Therapeutics Market Size by Type (2025-2030)

7.2.3 Europe Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

7.3 Europe Metabolic Disorder Therapeutics Market Size by Application

7.3.1 Europe Metabolic Disorder Therapeutics Market Size by Application (2019-2024)

7.3.2 Europe Metabolic Disorder Therapeutics Market Size by Application (2025-2030)

7.3.3 Europe Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

7.4 Europe Metabolic Disorder Therapeutics Market Size by Country

7.4.1 Europe Metabolic Disorder Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

7.4.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Metabolic Disorder Therapeutics Market Size (2019-2030)

8.2 China Metabolic Disorder Therapeutics Market Size by Type

8.2.1 China Metabolic Disorder Therapeutics Market Size by Type (2019-2024)

8.2.2 China Metabolic Disorder Therapeutics Market Size by Type (2025-2030)

8.2.3 China Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

8.3 China Metabolic Disorder Therapeutics Market Size by Application

8.3.1 China Metabolic Disorder Therapeutics Market Size by Application (2019-2024)

8.3.2 China Metabolic Disorder Therapeutics Market Size by Application (2025-2030)

8.3.3 China Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Metabolic Disorder Therapeutics Market Size (2019-2030)

9.2 Asia Metabolic Disorder Therapeutics Market Size by Type

9.2.1 Asia Metabolic Disorder Therapeutics Market Size by Type (2019-2024)

9.2.2 Asia Metabolic Disorder Therapeutics Market Size by Type (2025-2030)

9.2.3 Asia Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

9.3 Asia Metabolic Disorder Therapeutics Market Size by Application

9.3.1 Asia Metabolic Disorder Therapeutics Market Size by Application (2019-2024)

9.3.2 Asia Metabolic Disorder Therapeutics Market Size by Application (2025-2030)

9.3.3 Asia Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

9.4 Asia Metabolic Disorder Therapeutics Market Size by Region

9.4.1 Asia Metabolic Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Metabolic Disorder Therapeutics Market Size by Region (2019-2024)

9.4.3 Asia Metabolic Disorder Therapeutics Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type

10.2.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application

10.3.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country

10.4.1 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 Novo Nordisk A/S

11.1.1 Novo Nordisk A/S Company Details

11.1.2 Novo Nordisk A/S Business Overview

11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction

11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.1.5 Novo Nordisk A/S Recent Developments

11.2 Sanofi S.A.

11.2.1 Sanofi S.A. Company Details

11.2.2 Sanofi S.A. Business Overview

11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction

11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.2.5 Sanofi S.A. Recent Developments

11.3 Boehringer Ingelheim GmbH

11.3.1 Boehringer Ingelheim GmbH Company Details

11.3.2 Boehringer Ingelheim GmbH Business Overview

11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction

11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.3.5 Boehringer Ingelheim GmbH Recent Developments

11.4 Eli Lilly and Company

11.4.1 Eli Lilly and Company Company Details

11.4.2 Eli Lilly and Company Business Overview

11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction

11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.4.5 Eli Lilly and Company Recent Developments

11.5 Merck KgaA

11.5.1 Merck KgaA Company Details

11.5.2 Merck KgaA Business Overview

11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction

11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.5.5 Merck KgaA Recent Developments

11.6 Amgen, Inc.

11.6.1 Amgen, Inc. Company Details

11.6.2 Amgen, Inc. Business Overview

11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction

11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.6.5 Amgen, Inc. Recent Developments

11.7 AstraZeneca PLC

11.7.1 AstraZeneca PLC Company Details

11.7.2 AstraZeneca PLC Business Overview

11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction

11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.7.5 AstraZeneca PLC Recent Developments

11.8 Actelion Pharmaceuticals Ltd.

11.8.1 Actelion Pharmaceuticals Ltd. Company Details

11.8.2 Actelion Pharmaceuticals Ltd. Business Overview

11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction

11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.8.5 Actelion Pharmaceuticals Ltd. Recent Developments

11.9 Shire PLC

11.9.1 Shire PLC Company Details

11.9.2 Shire PLC Business Overview

11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction

11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.9.5 Shire PLC Recent Developments

11.10 AbbVie, Inc.

11.10.1 AbbVie, Inc. Company Details

11.10.2 AbbVie, Inc. Business Overview

11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction

11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.10.5 AbbVie, Inc. Recent Developments

11.11 Biocon Ltd.

11.11.1 Biocon Ltd. Company Details

11.11.2 Biocon Ltd. Business Overview

11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction

11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.11.5 Biocon Ltd. Recent Developments

11.12 BioMarin Pharmaceutical, Inc.

11.12.1 BioMarin Pharmaceutical, Inc. Company Details

11.12.2 BioMarin Pharmaceutical, Inc. Business Overview

11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction

11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.12.5 BioMarin Pharmaceutical, Inc. Recent Developments

11.13 Bristol-Myers Squibb Company

11.13.1 Bristol-Myers Squibb Company Company Details

11.13.2 Bristol-Myers Squibb Company Business Overview

11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction

11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.13.5 Bristol-Myers Squibb Company Recent Developments

11.14 Cipla, Inc.

11.14.1 Cipla, Inc. Company Details

11.14.2 Cipla, Inc. Business Overview

11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction

11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.14.5 Cipla, Inc. Recent Developments

11.15 CymaBay Therapeutics, Inc.

11.15.1 CymaBay Therapeutics, Inc. Company Details

11.15.2 CymaBay Therapeutics, Inc. Business Overview

11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction

11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)

11.15.5 CymaBay Therapeutics, Inc. Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Novo Nordisk A S

Sanofi

Boehringer Ingelheim GmbH

Eli Lilly and Company

Merck KGaA

Amgen Inc

Astrazeneca plc

Actelion Pharmaceuticals Ltd

Shire Plc

AbbVie

Biocon Ltd.

BioMarin Pharmaceutical Inc

Bristol Myers Squibb Company

Cipla Ltd

CymaBay Therapeutics Inc

List of Tables

Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Lysosomal Storage Diseases

Table 3. Key Players of Diabetes

Table 4. Key Players of Obesity

Table 5. Key Players of Inherited Metabolic Disorders

Table 6. Key Players of Hypercholesterolemia

Table 7. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 8. Global Metabolic Disorder Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Metabolic Disorder Therapeutics Market Share by Region (2019-2024)

Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Metabolic Disorder Therapeutics Market Share by Region (2025-2030)

Table 13. Metabolic Disorder Therapeutics Market Trends

Table 14. Metabolic Disorder Therapeutics Market Drivers

Table 15. Metabolic Disorder Therapeutics Market Challenges

Table 16. Metabolic Disorder Therapeutics Market Restraints

Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Metabolic Disorder Therapeutics Revenue Share by Players (2019-2024)

Table 19. Global Top Metabolic Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)

Table 20. Global Metabolic Disorder Therapeutics Industry Ranking 2022 VS 2023 VS 2024

Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 22. Global Key Players of Metabolic Disorder Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Metabolic Disorder Therapeutics, Product and Application

Table 24. Global Key Players of Metabolic Disorder Therapeutics, Product and Application

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2019-2024)

Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2025-2030)

Table 30. Global Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Metabolic Disorder Therapeutics Revenue Share by Application (2019-2024)

Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Metabolic Disorder Therapeutics Revenue Share by Application (2025-2030)

Table 34. North America Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 35. North America Metabolic Disorder Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 36. North America Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 37. North America Metabolic Disorder Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 38. North America Metabolic Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 40. North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 41. Europe Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 42. Europe Metabolic Disorder Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 43. Europe Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 44. Europe Metabolic Disorder Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 45. Europe Metabolic Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 47. Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 48. China Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 49. China Metabolic Disorder Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 50. China Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 51. China Metabolic Disorder Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 52. Asia Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 53. Asia Metabolic Disorder Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 54. Asia Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 55. Asia Metabolic Disorder Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 56. Asia Metabolic Disorder Therapeutics Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 57. Asia Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 58. Asia Metabolic Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Type (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Application (2025-2030) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 64. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 65. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 66. Novo Nordisk A/S Company Details

Table 67. Novo Nordisk A/S Business Overview

Table 68. Novo Nordisk A/S Metabolic Disorder Therapeutics Product

Table 69. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 70. Novo Nordisk A/S Recent Developments

Table 71. Sanofi S.A. Company Details

Table 72. Sanofi S.A. Business Overview

Table 73. Sanofi S.A. Metabolic Disorder Therapeutics Product

Table 74. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 75. Sanofi S.A. Recent Developments

Table 76. Boehringer Ingelheim GmbH Company Details

Table 77. Boehringer Ingelheim GmbH Business Overview

Table 78. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product

Table 79. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 80. Boehringer Ingelheim GmbH Recent Developments

Table 81. Eli Lilly and Company Company Details

Table 82. Eli Lilly and Company Business Overview

Table 83. Eli Lilly and Company Metabolic Disorder Therapeutics Product

Table 84. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 85. Eli Lilly and Company Recent Developments

Table 86. Merck KgaA Company Details

Table 87. Merck KgaA Business Overview

Table 88. Merck KgaA Metabolic Disorder Therapeutics Product

Table 89. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 90. Merck KgaA Recent Developments

Table 91. Amgen, Inc. Company Details

Table 92. Amgen, Inc. Business Overview

Table 93. Amgen, Inc. Metabolic Disorder Therapeutics Product

Table 94. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 95. Amgen, Inc. Recent Developments

Table 96. AstraZeneca PLC Company Details

Table 97. AstraZeneca PLC Business Overview

Table 98. AstraZeneca PLC Metabolic Disorder Therapeutics Product

Table 99. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 100. AstraZeneca PLC Recent Developments

Table 101. Actelion Pharmaceuticals Ltd. Company Details

Table 102. Actelion Pharmaceuticals Ltd. Business Overview

Table 103. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product

Table 104. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 105. Actelion Pharmaceuticals Ltd. Recent Developments

Table 106. Shire PLC Company Details

Table 107. Shire PLC Business Overview

Table 108. Shire PLC Metabolic Disorder Therapeutics Product

Table 109. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 110. Shire PLC Recent Developments

Table 111. AbbVie, Inc. Company Details

Table 112. AbbVie, Inc. Business Overview

Table 113. AbbVie, Inc. Metabolic Disorder Therapeutics Product

Table 114. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 115. AbbVie, Inc. Recent Developments

Table 116. Biocon Ltd. Company Details

Table 117. Biocon Ltd. Business Overview

Table 118. Biocon Ltd. Metabolic Disorder Therapeutics Product

Table 119. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 120. Biocon Ltd. Recent Developments

Table 121. BioMarin Pharmaceutical, Inc. Company Details

Table 122. BioMarin Pharmaceutical, Inc. Business Overview

Table 123. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product

Table 124. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 125. BioMarin Pharmaceutical, Inc. Recent Developments

Table 126. Bristol-Myers Squibb Company Company Details

Table 127. Bristol-Myers Squibb Company Business Overview

Table 128. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product

Table 129. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 130. Bristol-Myers Squibb Company Recent Developments

Table 131. Cipla, Inc. Company Details

Table 132. Cipla, Inc. Business Overview

Table 133. Cipla, Inc. Metabolic Disorder Therapeutics Product

Table 134. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 135. Cipla, Inc. Recent Developments

Table 136. CymaBay Therapeutics, Inc. Company Details

Table 137. CymaBay Therapeutics, Inc. Business Overview

Table 138. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product

Table 139. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)

Table 140. CymaBay Therapeutics, Inc. Recent Developments

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Metabolic Disorder Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Lysosomal Storage Diseases Features

Figure 4. Diabetes Features

Figure 5. Obesity Features

Figure 6. Inherited Metabolic Disorders Features

Figure 7. Hypercholesterolemia Features

Figure 8. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 9. Global Metabolic Disorder Therapeutics Market Share by Application: 2023 VS 2030

Figure 10. Oral Case Studies

Figure 11. Parenteral Case Studies

Figure 12. Others Case Studies

Figure 13. Metabolic Disorder Therapeutics Report Years Considered

Figure 14. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Metabolic Disorder Therapeutics Market Share by Region: 2023 VS 2030

Figure 17. Global Metabolic Disorder Therapeutics Market Share by Players in 2023

Figure 18. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2023

Figure 20. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

Figure 22. North America Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

Figure 23. North America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

Figure 24. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Metabolic Disorder Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 27. Europe Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

Figure 28. Europe Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

Figure 29. Europe Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

Figure 30. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. France Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Nordic Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. China Metabolic Disorder Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 37. China Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

Figure 38. China Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

Figure 39. Asia Metabolic Disorder Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 40. Asia Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

Figure 41. Asia Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

Figure 42. Asia Metabolic Disorder Therapeutics Market Share by Region (2019-2030)

Figure 43. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. China Taiwan Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. India Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Size YoY (2019-2030) & (US$ Million)

Figure 50. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Type (2019-2030)

Figure 51. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Application (2019-2030)

Figure 52. Middle East, Africa, and Latin America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)

Figure 53. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 54. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 55. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Israel Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. GCC Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 59. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 60. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 61. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 62. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 63. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 64. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 65. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 66. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 67. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 68. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 69. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 70. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 71. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 72. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 73. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)

Figure 74. Bottom-up and Top-down Approaches for This Report

Figure 75. Data Triangulation

Figure 76. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions